- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04324866
Prevalence and Incidence of COVID-19 Infection in Patients With Chronic Plaque Psoriasis on Immunosuppressant Therapy
March 26, 2020 updated by: Paolo Gisondi, Universita di Verona
This study will assess the prevalence and incidence of COVID-19 infection in patients with chronic plaque psoriasis on immunosuppressant therapy.
Study Overview
Status
Unknown
Conditions
Intervention / Treatment
Detailed Description
The ongoing COVID-19 pandemic has hit Northern Italy (including the Veneto region) particularly hard, causing several deaths and putting a huge strain on the Italian National Healthcare System.
In the absence of specific treatments, preventing the infection from spreading remains the only effective measure.
There is a lot of apprehension both from doctors (including dermatologists, rheumatologists and gastroenterologists) and their patients that immunosuppressive medications (biologics, methotrexate, ciclosporin and corticosteroids) might lead to an increased susceptibility to COVID-19 infection or negatively influence the course of the infection.
However, there is currently a lack of scientific evidence to recommend whether immunosuppressive treatments should or should not be continued in patients who have no symptoms of COVID-19 infection.
Besides, treatment discontinuation would cause flare-ups of diseases - such as plaque psoriasis, psoriatic arthritis and inflammatory bowel diseases - which are invalidating and have a relatively high prevalence in the Veneto population.
In the Unit of Dermatology of the Azienda Ospedaliera Universitaria Intergrata di Verona alone, more than 2000 patients are currently being treated with immunosuppressive agents.
As of now, there are no data available on the prevalence and incidence of COVID-19 infection in patients with immune-mediated diseases, nor can data from randomized clinical trials be extrapolated to the susceptibility to COVID-19 infection in patients on biologic drugs.
This study aims to assess the prevalence and incidence of COVID-19 infection in patients with chronic plaque psoriasis on immunosuppressive therapy and to identify associated risk factors.
Such data would prove invaluable for clinicians dealing with patients on immunosuppressive agents during the coronavirus outbreak.
Study Type
Observational
Enrollment (Anticipated)
300
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Paolo Gisondi
- Phone Number: +39 0458122547
- Email: paolo.gisondi@univr.it
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 75 years (ADULT, OLDER_ADULT)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Sampling Method
Non-Probability Sample
Study Population
This study will enroll patients from the Unit of Dermatology of Azienda Ospedaliera Universitaria di Verona and their partners.
Description
Group 1
Inclusion Criteria:
- Aged 18 to 75 years old
- Individuals with a clinical diagnosis of moderate-to-severe chronic plaque psoriasis confirmed by the Investigator
- Continuous immunosuppressive therapy (etanercept, adalimumab, infliximab, ustekinumab, secukinumab, ixekizumab, brodalumab, guselkumab, apremilast, methotrexate, ciclsoporin, acitretin) for the past 3 months
- Is willing and able to sign informed consent to participate
Exclusion Criteria:
- Patients unwilling to undergo noasopharyngeal swab
- Inability to give informed consent
Group 2
Inclusion Criteria:
- Aged 18 to 75 years old
- Partner of a patient with psoriasis enrolled in the study
- Is willing and able to sign informed consent to participate
Exclusion Criteria:
- Personal history of psoriasis
- Ongoing immunosuppressive therapy
- Patients unwilling to undergo noasopharyngeal swab
- Inability to give informed consent
Group 3
- Aged 18 to 75 years old
- Individuals with a clinical diagnosis of moderate-to-severe atopic dermatitis confirmed by the Investigator
- Continuous therapy with dupilumab for the past 3 months
- Is willing and able to sign informed consent to participate
Exclusion Criteria:
- Patients unwilling to undergo noasopharyngeal swab
- Inability to give informed consent
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Group 1
Patients with chronic plaque psoriasis on immunosuppressant therapy
|
Nasopharyngeal swab for the molecular diagnosis of COVID-19 infection
|
Group 2
Psoriatic patients' partners
|
Nasopharyngeal swab for the molecular diagnosis of COVID-19 infection
|
Group 3
Patients with atopic dermatitis treated with dupilumab
|
Nasopharyngeal swab for the molecular diagnosis of COVID-19 infection
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Point prevalence of COVID-19 infection
Time Frame: Baseline up to 6 months
|
Baseline up to 6 months
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Incidence of COVID-19 infection
Time Frame: Baseline up to 6 months
|
Baseline up to 6 months
|
Percentage of subjects presenting fever or respiratory symptoms
Time Frame: Baseline up to 6 months
|
Baseline up to 6 months
|
Evaluate the relationship between COVID-19 infection and chronic pharmacological treatments
Time Frame: Baseline up to 6 months
|
Baseline up to 6 months
|
Evaluate the relationship between COVID-19 infection and comorbid medical conditions
Time Frame: Baseline up to 6 months
|
Baseline up to 6 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (ANTICIPATED)
April 1, 2020
Primary Completion (ANTICIPATED)
November 1, 2020
Study Completion (ANTICIPATED)
December 1, 2020
Study Registration Dates
First Submitted
March 24, 2020
First Submitted That Met QC Criteria
March 26, 2020
First Posted (ACTUAL)
March 27, 2020
Study Record Updates
Last Update Posted (ACTUAL)
March 27, 2020
Last Update Submitted That Met QC Criteria
March 26, 2020
Last Verified
March 1, 2020
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Pathologic Processes
- Skin Diseases
- Coronaviridae Infections
- Nidovirales Infections
- RNA Virus Infections
- Virus Diseases
- Respiratory Tract Infections
- Respiratory Tract Diseases
- Pneumonia, Viral
- Pneumonia
- Lung Diseases
- Disease Attributes
- Skin Diseases, Papulosquamous
- COVID-19
- Coronavirus Infections
- Infections
- Communicable Diseases
- Psoriasis
Other Study ID Numbers
- Gisondi 4
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Coronavirus Infection
-
The University of Hong KongHospital Authority, Hong KongCompletedNovel Coronavirus InfectionHong Kong
-
Affiliated Hospital to Academy of Military Medical...Beijing 302 HospitalUnknownNovel Coronavirus Infection PneumoniaChina
-
ProgenaBiomeDSCS CRORecruitingCOVID-19 | Coronavirus Infection | COVID | Corona Virus Infection | Coronavirus | Sars-CoV2 | Coronavirus-19 | Coronavirus 19United States
-
AudibleHealth AI, Inc.Sunrise Research Institute; Analytical Solutions Group, Inc.; Kelley Medical... and other collaboratorsCompletedCoronavirus Disease 2019 | SARS-CoV-2 Infection | COVID-19 Pandemic | COVID-19 Virus Infection | Coronavirus Disease-19 | COVID-19 Virus Disease | 2019 Novel Coronavirus Disease | 2019 Novel Coronavirus Infection | 2019-nCoV DiseaseUnited States
-
Concern GRANITSamara State Medical UniversityCompletedCoronavirus Infection COVID-19Russian Federation
-
D'Or Institute for Research and EducationUnknown
-
Institut National de la Santé Et de la Recherche...Recruiting
-
Kansas City Heart Rhythm InstituteTerminated
-
Universidade Federal de Sao CarlosTerminatedCoronavirus InfectionBrazil
-
Chelsea and Westminster NHS Foundation TrustUnknownCOVID-19 | COVID-19 Infection | 2019 Novel Coronavirus InfectionUnited Kingdom
Clinical Trials on Nasopharyngeal swab
-
LumiraDx UK LimitedActive, not recruitingCOVID-19United States
-
Public Health EnglandCompletedNasal Carriage of PneumococciUnited Kingdom
-
Assistance Publique Hopitaux De MarseilleCompleted
-
Assistance Publique Hopitaux De MarseilleCompleted
-
Assistance Publique Hopitaux De MarseilleCompleted
-
St. Jude Children's Research HospitalNational Institute of Allergy and Infectious Diseases (NIAID); The University...Completed
-
Wyeth is now a wholly owned subsidiary of PfizerCompletedStreptococcus Pneumoniae InfectionsChina
-
Medical University InnsbruckUnknown
-
Butantan InstituteCompleted
-
Assistance Publique - Hôpitaux de ParisRecruitingSARS-CoV2 Infection | Mutation | COVID-19 Acute Respiratory Distress SyndromeFrance